Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Merus N.V. CS UPPSALALAAN 17 UTRECHT P7 3584 NLD

www.merus.nl Employees: 229 P: 31-85-016-2500

Description:

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

Key Statistics

Overview:

Market Capitalization, $K 2,865,218
Enterprise Value, $K 2,660,968
Shares Outstanding, K 68,464
Annual Sales, $ 43,950 K
Annual Net Income, $ -154,940 K
Last Quarter Sales, $ 11,770 K
Last Quarter Net Income, $ -99,910 K
EBIT, $ -230,950 K
EBITDA, $ -228,410 K
60-Month Beta 1.07
% of Insider Shareholders 4.57%
% of Institutional Shareholders 96.14%
Float, K 65,335
% Float 95.43%
Short Volume Ratio 0.20

Growth:

1-Year Return 61.71%
3-Year Return 29.81%
5-Year Return 172.28%
5-Year Revenue Growth 18.34%
5-Year Earnings Growth -63.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.95 on 10/31/24
Next Earnings Date 11/07/24
Earnings Per Share ttm -3.44
EPS Growth vs. Prev Qtr -17.28%
EPS Growth vs. Prev Year -120.93%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MRUS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -38.89%
Return-on-Assets % -31.16%
Profit Margin % -352.54%
Debt/Equity 0.00
Price/Sales 65.57
Price/Cash Flow N/A
Price/Book 4.10
Book Value/Share 10.27
Interest Coverage -1.54
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar